'Benign' malaria key driver of human evolution in Asia-Pacific

September 4, 2012

The malaria species rampant in the Asia-Pacific region has been a significant driver of evolution of the human genome, a new study has shown. An international team of researchers has shown that Plasmodium vivax malaria, the most prevalent malaria species in the Asia-Pacific, is a significant cause of genetic evolution that provides protection against malaria.

Their finding challenges the widely-accepted theory that Plasmodium falciparum, which causes the most lethal form of , is the only capable of driving genome evolution in humans. The study was published today in the journal .

Professor Ivo Mueller from the Walter and Eliza Hall Institute and Barcelona Centre for International Health Research (CRESIB) led the study, with colleagues from the Papua New Guinea Institute of Medical Research, Centre of Global Health and Diseases, US, and the University of Western Australia.

Malaria is a devastating that kills up to one million people a year. It is a major cause of poverty and a barrier to economic development. Approximately half of the world's population is at risk of .

"Humans and malaria parasites have been co-evolving for thousands of years," Professor Mueller said. "Malaria has been a major force in the evolution of the human genome, with gene mutations that provide humans with some protection against the disease being preserved through natural selection because they aid in survival."

Professor Mueller said the study has challenged the perception that P. falciparum malaria is the only malaria species that affects evolution. "It has long been assumed that , the species that causes the most severe disease and most deaths from malaria, is the most important driver of this gene selection in humans," Professor Mueller said. "Our results suggest that P. vivax malaria, though until recently widely considered to be a 'benign' form of malaria, actually causes severe enough disease to provide evolutionary selection pressures in the Asia-Pacific."

Professor Mueller said that the research team was interested in whether P. vivax malaria might be the cause of the unusually high rates of Southeast Asian ovalocytosis (SAO), a hereditary red blood cell disorder, in the Asia-Pacific region. "SAO occurs in approximately 10 to 15 per cent of the population in parts of the South West Pacific and is caused by a hereditary mutation in a single copy of a gene that makes a red blood cell membrane protein. This is almost an absurdly high frequency when you consider that inheriting two copies of the mutation is invariably fatal, so we figured it must confer a strong advantage to the carriers," he said.

The research team looked at the incidence of P. vivax and P. falciparum infections in three studies that included a total of 1975 children in aged 0-14 years. "We found that SAO-positive children were significantly protected against P. vivax infection, with 46 per cent reduction of clinical disease in infants with little or no immunity, and 52-55 per cent reduction in the risk of infection in older children. We also saw a significant decrease in parasite numbers in infants and older children, which is linked to a decrease in risk of clinical disease," Professor Mueller said.

The finding could have dramatic implications for future malaria vaccine design and development, Professor Mueller said. "Studying the mechanisms that cause SAO-positive people to be protected against P. vivax malaria could help us to better understand the mechanics of infection and help us to identify better targets for a malaria vaccine," he said.

Explore further: Combination drug treatment can cut malaria by 30 percent

Related Stories

Combination drug treatment can cut malaria by 30 percent

April 2, 2012
Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.

New technology improves malaria control and vaccine development

June 5, 2012
A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines.

Improving human immunity to malaria

August 1, 2012
The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells.

Sequencing of malaria genomes reveals challenges, opportunities in battle against parasite

August 5, 2012
Genetic variability revealed in malaria genomes newly sequenced by two multi-national research teams points to new challenges in efforts to eradicate the parasite, but also offers a clearer and more detailed picture of its ...

Monkeys provide reservoir for human malaria in South-east Asia

April 7, 2011
Monkeys infected with an emerging malaria strain are providing a reservoir for human disease in South-east Asia, according to research published today. The Wellcome Trust-funded study confirms that the species has not yet ...

Recommended for you

Gene therapy improves immunity in babies with 'bubble boy' disease

December 9, 2017
Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. ...

In lab research, scientists slow progression of a fatal form of muscular dystrophy

December 8, 2017
In a paper published in the Nature journal Scientific Reports, Saint Louis University (SLU) researchers report that a new drug reduces fibrosis (scarring) and prevents loss of muscle function in an animal model of Duchenne ...

Double-blind study shows HIV vaccine not effective in viral suppression

December 7, 2017
(Medical Xpress)—A large team of researchers from the U.S. and Canada has conducted a randomized double-blind study of the effectiveness of an HIV vaccine and has found it to be ineffective in suppressing the virus. In ...

Time matters: Does our biological clock keep cancer at bay?

December 7, 2017
Our body has an internal biological or "circadian" clock, which cycles daily and is synchronized with solar time. New research done in mice suggests that it can help suppress cancer. The study, publishing 7 December in the ...

Novel harvesting method rapidly produces superior stem cells for transplantation

December 7, 2017
A new method of harvesting stem cells for bone marrow transplantation - developed by a team of investigators from the Massachusetts General Hospital (MGH) Cancer Center and the Harvard Stem Cell Institute - appears to accomplish ...

Inhibiting TOR boosts regenerative potential of adult tissues

December 7, 2017
Adult stem cells replenish dying cells and regenerate damaged tissues throughout our lifetime. We lose many of those stem cells, along with their regenerative capacity, as we age. Working in flies and mice, researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.